Sprint Bioscience AB (SPRINT) AI Stock Analysis

• Market Cap: kr198.37M
• Dividend Yield: N/A
• Average Volume (3M): 560.98K
• Price to Earnings (P/E): 2.3
• Beta (1Y): 1.28
• Revenue Growth: -17.80%
• EPS Growth: -11.96%
• Country: SE
• Employees: 38
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.07
• Shares Outstanding: 105,515,540
• 10 Day Avg. Volume: 1,502,692
• 30 Day Avg. Volume: 560,983
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.14
• Price to Sales (P/S): 0.81
• P/FCF Ratio: 1.63
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): kr99.40M

• Rating: 79 Outperform
• Price Target: kr2.50 ▲(68.92% Upside)
• Action: Upgraded Date: 02/18/26
• Date: Action: Upgraded 02/18/26

Score is driven mainly by improved financial performance (strong 2025 profitability and a debt-free balance sheet) and supportive valuation (very low P/E). Technicals are positive due to a clear uptrend, but overbought momentum indicators add near-term risk.

Positive Factors

Zero reported debt

Zero reported debt materially lowers financing risk for an early‑stage biotech. With no scheduled interest payments, the company has greater optionality to time equity or partnership financings, negotiate license deals, and avoid near‑term insolvency pressure while advancing preclinical programs.

Out‑licensing, partner-driven revenue model

A business model focused on discovering assets and out‑licensing shifts later‑stage capital and commercialization risk to partners. Structurally, this asset‑light approach allows Sprint to monetize programs through upfronts, milestones and royalties without building a costly commercial infrastructure.

Lean operating structure

A small, specialized headcount indicates low fixed overhead versus full‑scale biopharma. This lean setup helps preserve runway between financings, lets management concentrate resources on high‑value discovery projects, and supports flexible scaling when partner deals materialize.

Negative Factors

Declining revenue trend

A ~16% TTM revenue decline signals weakening partner income or fewer licensing milestones. Sustained top‑line contraction undermines internal funding capacity, reduces negotiating leverage with potential partners, and may reflect pipeline or commercialization attractiveness issues that harm long‑term viability.

Material cash burn

Significant negative operating and free cash flow means the business is not self‑funding and will require external capital to progress programs. This persistent burn increases dilution or refinancing risk, constrains the ability to advance multiple assets, and forces prioritization away from broader pipeline development.

Deep losses and equity erosion

Large accumulated losses and a sharply reduced equity base reflect value erosion and weaken the balance sheet. This limits financial flexibility, heightens dependence on dilutive raises or partner funding, and reduces the company's ability to absorb development setbacks without impairing shareholder value.

Sprint Bioscience AB Business Overview & Revenue Model

Company Description

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.

How the Company Makes Money

Sprint Bioscience generates revenue primarily through collaboration and licensing agreements with larger pharmaceutical companies. By advancing its drug candidates to a preclinical stage, the company positions itself to enter partnerships where it grants rights to its drug candidates in exchange for upfront payments, milestone payments, and royalties on future sales. These partnerships allow Sprint Bioscience to leverage the resources and expertise of established pharma companies to bring its innovations to market. Additionally, the company may receive government grants or research funding to support its development projects, although these are not its primary revenue streams.

Sprint Bioscience AB Financial Statement Overview

Summary

Strong 2025 step-change with material revenue growth, a return to substantial profitability, and a debt-free balance sheet. Main risk is high volatility and lower predictability given prior years’ losses and uneven cash flows.

Income Statement

The income statement shows a sharp profitability inflection in 2025, with revenue up materially year-over-year and net income strongly positive after multiple loss-making years (2020–2024). Gross profit also improved meaningfully versus 2024, suggesting better operating leverage or milestone/license-type revenue. The key weakness is volatility: results swung from heavy losses (notably 2022 and 2024) to very strong profits in 2025, which can be common in biotech but lowers predictability and makes the earnings base less stable.

Balance Sheet

The balance sheet is conservatively positioned with zero debt in recent years (2021–2025), reducing financial risk and refinancing pressure. Equity and total assets rose sharply in 2025 versus 2024, consistent with the strong profit year and improved capitalization. The main caution is historical instability in equity levels (e.g., a very low equity base in 2024), which indicates prior funding/burn sensitivity even if leverage is currently minimal.

Cash Flow

Cash generation improved dramatically in 2025, with operating cash flow and free cash flow turning strongly positive after negative free cash flow in 2024 and earlier years (except 2023). However, free cash flow growth is sharply negative in 2025 due to the swing from negative to positive being measured off a negative base, and overall cash flow has been uneven year-to-year—highlighting dependence on timing of receipts and the inherent lumpiness typical in biotechnology business models.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	167.17M	65.64M	50.48M	83.00K	35.11M
Gross Profit	97.33M	37.30M	41.79M	-60.91M	24.68M
EBITDA	98.40M	-17.32M	396.00K	-60.00M	-24.49M
Net Income	91.74M	-18.28M	-438.00K	-60.17M	-25.35M
Balance Sheet
Total Assets	136.66M	42.05M	62.38M	37.42M	79.14M
Cash, Cash Equivalents and Short-Term Investments	126.70M	25.06M	49.93M	29.49M	70.64M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	17.48M	32.78M	34.60M	9.23M	8.68M
Stockholders Equity	119.18M	9.27M	27.77M	28.19M	70.45M
Cash Flow
Free Cash Flow	83.44M	-24.65M	20.42M	-59.05M	-42.82M
Operating Cash Flow	83.53M	-23.36M	22.87M	-59.05M	-40.12M
Investing Cash Flow	-54.00K	-1.30M	-2.45M	0.00	-2.71M
Financing Cash Flow	18.17M	-225.00K	24.00K	17.90M	86.39M

Sprint Bioscience AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPRINT, the sentiment is Positive. The current price of 1.48 is below the 20-day moving average (MA) of 1.98, below the 50-day MA of 1.70, and above the 200-day MA of 0.93, indicating a neutral trend. The MACD of 0.12 indicates Positive momentum. The RSI at 48.33 is Neutral, neither overbought nor oversold. The STOCH value of 23.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SPRINT.

Sprint Bioscience AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SPRINT	79 Outperform	kr198.37M	2.26	-264.12%	―	-17.80%	-11.96%
2CUREX	54 Neutral	kr39.91M	-15.29	-304.59%	11.26%	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CMOTEC.B	45 Neutral	kr89.09M	-10.41	-114.00%	―	132.07%	54.65%
LARK	43 Neutral	kr43.36M	-3.57	―	8.47%	-94.12%	-25.83%
EXPRS2	40 Underperform	kr24.18M	-0.50	-88.65%	―	8.46%	11.73%